Compare Enbridge Inc (ENB) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enbridge Inc vs Novavax Inc — how do they compare? Enbridge Inc trades at $46.6 (market cap $103.38B), while Novavax Inc trades at $12.75 (market cap $1.82B). The key difference: Enbridge Inc is far larger — about 56.8× Novavax Inc's market cap, and Enbridge Inc pays a 6.02% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enbridge Inc for 91 Days and Novavax Inc for 59 Days on average.
| ENB | NVAX | |
|---|---|---|
Market Cap | $103.38B | $1.82B |
Volume | 3,684,305 | 6,198,505 |
Sector | Energy | Health |
52-Week High | $58.04 | $12.56 |
52-Week Low | $45.23 | $6.22 |
Typical Hold Time | 91 Days | 59 Days |
Enterprise Value | $185.39B | $1.39B |
Dividend Yield | 6.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENB trades at $46.54, up 1.42% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $65.19B in 2025, and the dividend yield is attractive at approximately 6% based on the recent $0.97 payout. Analyst consensus is mixed with a $61.63 price target, indicating potential upside from current levels.
The outlook for ENB is supported by stable cash flows and a secured project backlog, but risks include high debt levels and sensitivity to interest rates. Investment opportunity lies in the dividend income and valuation discount to analyst targets, though investors face headwinds from energy market volatility and rising leverage.
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and strong analyst support (73.9% buy ratings). The company reported revenue of $1.12B in 2025 with a net income of $440.3M, marking a significant turnaround from prior losses, though 2026 projections show a return to negative net income. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: strong valuation ratios (P/E of 3.14, EV/EBITDA of 1.72) and recent earnings beats suggest undervaluation, but persistent cash burn and negative equity pose risks. Investment opportunity lies in partnership-driven growth, while risks include execution challenges and reliance on vaccine demand. Wall Street sentiment remains optimistic despite fundamental volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
